HeyJaredTech and Drugs - Podcast
Welcome to Tech and Drugs, the podcast exploring how data and AI are revolutionizing Pharma and Biotech. Each episode features candid conversations with industry experts tackling real-world challenges, sharing success stories, and lessons learned.
- Indexed episodes, last 90 days
- 4
- Latest publication
- Sep 22, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 8, 2026
Latest episodes
From LIMS to Autonomous AI Scientists — Kevin Cramer (Sigmatic Sciences) | Tech & Drugs (opens the original)
Read excerpt
Kevin Cramer has spent over two decades in lab informatics. He founded Sapio Sciences, unifying LIMS and electronic lab notebooks into a single R&D platform, and now leads Sigmatic Sciences, building autonomous, agentic AI systems and Scout — an AI scientist built for the wet lab.In this episode of Tech & Drugs, Kevin and Thibault Géoui get into why pharma was great at science but treated software as an afterthought, why "how do I get data OUT of the system" was the question nobody asked, and wh
Making “Undruggable” Proteins Druggable? | Dr. Linker & Dr. Schnee, Merck KGaA, Darmstadt, Germany (opens the original)
Read excerpt
In this episode of Tech & Drugs, I sit down with Dr. Stephanie Linker and Dr. Philipp Schnee from Merck KGaA, Darmstadt, Germany to explore how AI is changing protein design, drug discovery, and the role of scientists.We discuss de novo protein design, structure prediction, AlphaFold, scientific agents, AI adoption, and what happens when computational models suggest biological solutions that scientists might never have considered themselves.Stephanie works as a Senior Computational Biochemist in
When AI Generates the Scientific Hypothesis | Mathieu Bourdenx, UK Dementia Research Institute @UCL (opens the original)
Read excerpt
In this Tech & Drugs episode, I sit down with Mathieu Bourdenx, Group Leader at the UK Dementia Research Institute / UCL, to explore how AI agents and AI co-scientists are beginning to change neuroscience research.We discuss brain aging, Alzheimer’s disease, dementia, systems biology, Kosmos, Open Scientist, CBrain, and what it means to work with AI tools that can search literature, analyze data, generate hypotheses, and support scientific discovery.Mathieu’s research focuses on brain aging and
Can AI Reduce Animal Testing in Toxicology? With Dr. Thomas Steger-Hartmann (opens the original)
Read excerpt
In this Tech & Drugs episode, I sit down with Thomas Steger-Hartmann, former investigational toxicology lead at Bayer and industry lead of the VICTOR Consortium, to explore the future of drug safety.We discuss how toxicology is moving from descriptive animal studies toward more predictive, data-driven, and less animal-dependent approaches — without losing sight of the ultimate goal: protecting patients.Thomas explains why animal models are often more useful than public debates suggest, where the
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.